Baseline characteristics of CSRG patients, according to immunosuppressant status.
| Characteristic | Patients Currently Taking Immunosuppressants, n = 183 | Patients Not Currently Taking Immunosuppressants, n = 851 | p |
|---|---|---|---|
| Age, yrs | 51.7 | 56.1 | < 0.001 |
| Women, % | 80.9 | 87.4 | 0.03 |
| Disease duration, yrs | 7.35 | 11.77 | < 0.001 |
| Disease subset, % | |||
| Limited | 37.9 | 63.7 | < 0.001 |
| Diffuse | 61.0 | 32.5 | < 0.001 |
| Skin score (range 0–51) | 14.2 | 9.3 | < 0.001 |
| Patients with interstitial lung disease, % | 42.8 | 33.1 | 0.03 |
| Pulmonary function test, % predicted | |||
| FVC | 87.3 | 91.4 | 0.03 |
| DLCO | 69.1 | 71.6 | 0.02 |
| Physician global assessments (range 0–10) | |||
| Disease activity | 3.3 | 2.7 | < 0.001 |
| Disease severity | 3.2 | 2.2 | < 0.001 |
| Disease damage | 4.1 | 3.2 | < 0.001 |
| SSc-related autoantibodies, % | |||
| Topoisomerase | 25.0 | 13.3 | < 0.001 |
| Centromere | 10.8 | 39.6 | < 0.001 |
| RNA polymerase III | 22.9 | 14.6 | 0.02 |
| Pm/Scl | 17.9 | 16.9 | 0.89 |
| Proportion receiving corticosteroids, % | 33.3 | 10.8 | < 0.001 |
FVC: forced vital capacity; DLCO: diffusing capacity of the lung for carbon monoxide.